Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals to Report Fourth Quarter and Year End 2015 Results on March 10, 2016
Conference Call Scheduled for 8:30 a.m. EST

BOSTON, Feb. 25, 2016 /PRNewswire/ -- The management team of women's health therapeutics developer Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), will hold a conference call on March 10, 2016, to discuss financial results of the fourth quarter and year ended December 31, 2015.  The call details are as follows:


Thursday, March 10, 2016


8:30 a.m. EST

Dial-in numbers:

Toll free: (866) 374-4635 (U.S.), (855) 669-9657 (Canada), or

International: (412) 902-4218

Webcast (live & archive):, under 'Investors' or click here

The teleconference replay will be available at approximately one hour after completion through Wednesday, March 16, 2016, at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International). The conference ID for the replay is 10081480. 

The archived webcast will be available for one year via the aforementioned URLs.

Juniper Pharmaceuticals, Inc. (PRNewsFoto/Juniper Pharmaceuticals, Inc.)

About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics that address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage novel intra-vaginal drug delivery technologies.  Juniper's commercial product, CRINONE® 8% (progesterone gel), is marketed by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide and by Allergan, Inc. in the U.S. Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

CRINONE® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 /

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.

Follow us on LinkedIn  

Logo -

To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.